Biofil Chemicals & Pharmaceuticals Ltd
Fundamental Score
Biofil Chemicals & Pharmaceuticals Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of BIOFILCHEM across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Attractive Valuation (P/E: 21.13 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Robust Profit Growth (300.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Revenue Growth (461.83%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (112.67x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
10 factors identified
Below-Average Return on Equity (3.03%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (4.12%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Margin Pressure Concerns (3.56%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges. Monitor for operational improvements.
Limited Growth History (2.38% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.
Weak Earnings Growth (-14.28% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Stagnant Profit Growth (-14.28% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity. Assess transformation initiatives.
Limited Institutional Interest (FII+DII: 0.08%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Biofil Chemicals & Pharmaceuticals Ltd
About BIOFILCHEM
Business Overview
Biofil Chemicals and Pharmaceuticals Limited engages in manufacturing and trading of pharmaceuticals in India. It operates through Pharmaceutical and Chemical divisions. The company offers basic drugs and chemicals, such as sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumerate, micro crystalline cellulose, and dicyclomine hydrochloride; and packaging solutions. It also provides job work service for manufacturing pharmaceutical drugs. Biofil Chemicals and Pharmaceuticals Limited was incorporated in 1985 and is based in Indore, India.
Company Details
Key Leadership
BIOFILCHEM Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM)?
As of 03 Feb 2026, 01:03 pm IST, Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) is currently trading at ₹46.34. The stock has a market capitalization of ₹60.21 (Cr).
Is BIOFILCHEM share price Overvalued or Undervalued?
BIOFILCHEM is currently trading at a P/E ratio of 21.13x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Biofil Chemicals & Pharmaceuticals Ltd share price?
Key factors influencing BIOFILCHEM's price include its quarterly earnings growth (Sales Growth: 461.83%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Biofil Chemicals & Pharmaceuticals Ltd a good stock for long-term investment?
Biofil Chemicals & Pharmaceuticals Ltd shows a 5-year Profit Growth of -14.28% and an ROE of 3.03%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing.
How does Biofil Chemicals & Pharmaceuticals Ltd compare with its industry peers?
Biofil Chemicals & Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare BIOFILCHEM's P/E of 21.13x and ROE of 3.03% against the industry averages to determine its competitive standing.
What is the P/E ratio of BIOFILCHEM and what does it mean?
BIOFILCHEM has a P/E ratio of 21.13x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹21 for every ₹1 of annual earnings.
How is BIOFILCHEM performing according to Bull Run's analysis?
BIOFILCHEM has a Bull Run fundamental score of 45.4/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does BIOFILCHEM belong to?
BIOFILCHEM operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Biofil Chemicals & Pharmaceuticals Ltd.
What is Return on Equity (ROE) and why is it important for BIOFILCHEM?
BIOFILCHEM has an ROE of 3.03%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Biofil Chemicals & Pharmaceuticals Ltd generates profits from shareholders' equity.
How is BIOFILCHEM's debt-to-equity ratio and what does it indicate?
BIOFILCHEM has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is BIOFILCHEM's dividend yield and is it a good dividend stock?
BIOFILCHEM offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has BIOFILCHEM grown over the past 5 years?
BIOFILCHEM has achieved 5-year growth rates of: Sales Growth 2.38%, Profit Growth -14.28%, and EPS Growth -14.28%.
What is the promoter holding in BIOFILCHEM and why does it matter?
Promoters hold 46.79% of BIOFILCHEM shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is BIOFILCHEM's market capitalization category?
BIOFILCHEM has a market capitalization of ₹60 crores, placing it in the Small-cap category.
How volatile is BIOFILCHEM stock?
BIOFILCHEM has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for BIOFILCHEM?
BIOFILCHEM has a 52-week high of ₹N/A and low of ₹N/A.
What is BIOFILCHEM's operating profit margin trend?
BIOFILCHEM has a 5-year average Operating Profit Margin (OPM) of 3.56%, indicating the company's operational efficiency.
How is BIOFILCHEM's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 461.83% and YoY Profit Growth of 300.00%.
What is the institutional holding pattern in BIOFILCHEM?
BIOFILCHEM has FII holding of 0.00% and DII holding of 0.08%. Significant institutional holding often suggests professional confidence in the stock.